DNA损伤修复在肝癌中的研究进展

doi:10.3760/cma.j.cn371439-20220520-00127

摘要/Abstract

摘要：

DNA损伤修复（DDR）基因在肝癌中存在过表达的现象。研究发现，DDR与肝癌的发生与发展有密切的联系。DDR抑制剂与肝癌化疗、靶向治疗药物间存在协同作用，其可增强放疗的敏感性。部分DDR基因可作为肝癌预后评估的生物标志物。

Abstract:

DNA damage repair （DDR） genes are overexpressed in liver cancer. Studies have found that DDR is closely related to the occurrence and development of liver cancer. There is a synergistic effect between DDR inhibitors and chemotherapy and targeted drugs for liver cancer. DDR inhibitors can enhance the sensitivity of radiotherapy. Some DDR genes can be used as biomarkers for the prognosis of liver cancer.

Key words: DNA damage, Liver neoplasms, DNA repair, Combined modality therapy, Prognosis

狄伟华, 赵雪梅. DNA损伤修复在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(10): 635-638.

Di Weihua, Zhao Xuemei. Research progress on the relationship between DNA damage repair genes and liver cancer[J]. Journal of International Oncology, 2022, 49(10): 635-638.

参考文献 30

[1]	Gillman R, Lopes Floro K, Wankell M, et al. The role of DNA damage and repair in liver cancer[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(1): 188493. DOI: 10.1016/j.bbcan.2020.188493. doi: 10.1016/j.bbcan.2020.188493
[2]	Lin J, Shi J, Guo H, et al. Alterations in DNA damage repair genes in primary liver cancer[J]. Clin Cancer Res, 2019, 25(15): 4701-4711. DOI: 10.1158/1078-0432.CCR-19-0127. doi: 10.1158/1078-0432.CCR-19-0127 pmid: 31068370
[3]	Xiong Y, Zhang Q, Ye J, et al. Associations between three XRCC1 polymorphisms and hepatocellular carcinoma risk: a meta-analysis of case-control studies[J]. PLoS One, 2018, 13(11): e0206853. DOI: 10.1371/journal.pone.0206853. doi: 10.1371/journal.pone.0206853
[4]	Kumar N, Raja S, Van Houten B. The involvement of nucleotide excision repair proteins in the removal of oxidative DNA damage[J]. Nucleic Acids Res, 2020, 48(20): 11227-11243. DOI: 10.1093/nar/gkaa777. doi: 10.1093/nar/gkaa777 pmid: 33010169
[5]	Zhuo Z, Miao L, Hua W, et al. Genetic variations in nucleotide excision repair pathway genes and hepatoblastoma susceptibility[J]. Int J Cancer, 2021, 149(9): 1649-1658. DOI: 10.1002/ijc.33722. doi: 10.1002/ijc.33722
[6]	Saha J, Bae J, Wang SY, et al. Ablating putative Ku70 phosphorylation sites results in defective DNA damage repair and spontaneous induction of hepatocellular carcinoma[J]. Nucleic Acids Res, 2021, 49(17): 9836-9850. DOI: 10.1093/nar/gkab743. doi: 10.1093/nar/gkab743 pmid: 34428289
[7]	Yue X, Bai C, Xie D, et al. DNA-PKcs: a multi-faceted player in DNA damage response[J]. Front Genet, 2020, 11: 607428. DOI: 10.3389/fgene.2020.607428. doi: 10.3389/fgene.2020.607428
[8]	Pannunzio NR, Watanabe G, Lieber MR. Nonhomologous DNA end-joining for repair of DNA double-strand breaks[J]. J Biol Chem, 2018, 293(27): 10512-10523. DOI: 10.1074/jbc.TM117.000374. doi: 10.1074/jbc.TM117.000374 pmid: 29247009
[9]	Ma M, Rodriguez A, Sugimoto K. Activation of ATR-related protein kinase upon DNA damage recognition[J]. Curr Genet, 2020, 66(2): 327-333. DOI: 10.1007/s00294-019-01039-w. doi: 10.1007/s00294-019-01039-w pmid: 31624858
[10]	Ge C, Vilfranc CL, Che L, et al. The BRUCE-ATR signaling axis is required for accurate DNA replication and suppression of liver cancer development[J]. Hepatology, 2019, 69(6): 2608-2622. DOI: 10.1002/hep.30529. doi: 10.1002/hep.30529 pmid: 30693543
[11]	朱柯亭, 武振汝, 卢徐锋, 等. 肝细胞肝癌中HDAC3的表达及临床意义[J]. 世界华人消化杂志, 2017, 25(10): 922-928. DOI: 10.11569/wcjd.v25.i10.922. doi: 10.11569/wcjd.v25.i10.922
[12]	Ji H, Zhou Y, Zhuang X, et al. HDAC3 deficiency promotes liver cancer through a defect in H3K9ac/H3K9me3 transition[J]. Cancer Res, 2019, 79(14): 3676-3688. DOI: 10.1158/0008-5472.CAN-18-3767. doi: 10.1158/0008-5472.CAN-18-3767 pmid: 31097476
[13]	Boege Y, Malehmir M, Healy ME, et al. A dual role of caspase-8 in triggering and sensing proliferation-associated DNA damage, a key determinant of liver cancer development[J]. Cancer Cell, 2017, 32(3): 342-359.e10. DOI: 10.1016/j.ccell.2017.08.010. doi: S1535-6108(17)30354-9 pmid: 28898696
[14]	Mo J, Liang H, Su C, et al. DDX3X: structure, physiologic functions and cancer[J]. Mol Cancer, 2021, 20(1): 38. DOI: 10.1186/s12943-021-01325-7. doi: 10.1186/s12943-021-01325-7 pmid: 33627125
[15]	Chan CH, Chen CM, Lee YW, et al. DNA damage, liver injury, and tumorigenesis: consequences of DDX3X loss[J]. Mol Cancer Res, 2019, 17(2): 555-566. DOI: 10.1158/1541-7786.MCR-18-0551. doi: 10.1158/1541-7786.MCR-18-0551
[16]	Shen J, Chen M, Lee D, et al. Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression[J]. Gut, 2020, 69(2): 329-342. DOI: 10.1136/gutjnl-2019-318668. doi: 10.1136/gutjnl-2019-318668 pmid: 31439637
[17]	Goldstein M, Kastan MB. The DNA damage response: implications for tumor responses to radiation and chemotherapy[J]. Annu Rev Med, 2015, 66: 129-143. DOI: 10.1146/annurev-med-081313-121208. doi: 10.1146/annurev-med-081313-121208 pmid: 25423595
[18]	Chen CC, Chen CY, Cheng SF, et al. Hydroxygenkwanin increases the sensitivity of liver cancer cells to chemotherapy by inhibiting DNA damage response in mouse xenograft models[J]. Int J Mol Sci, 2021, 22(18): 9766. DOI: 10.3390/ijms22189766. doi: 10.3390/ijms22189766
[19]	Herath NI, Devun F, Herbette A, et al. Potentiation of doxorubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models[J]. Eur Radiol, 2017, 27(10): 4435-4444. DOI: 10.1007/s00330-017-4792-1. doi: 10.1007/s00330-017-4792-1 pmid: 28374075
[20]	Chen CC, Chen CY, Ueng SH, et al. Corylin increases the sensitivity of hepatocellular carcinoma cells to chemotherapy through long noncoding RNA RAD51-AS1-mediated inhibition of DNA repair[J]. Cell Death Dis, 2018, 9(5): 543. DOI: 10.1038/s41419-018-0575-0. doi: 10.1038/s41419-018-0575-0
[21]	Wang C, Tang H, Geng A, et al. Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors[J]. Proc Natl Acad Sci U S A, 2020, 117(42): 26356-26365. DOI: 10.1073/pnas.2002917117. doi: 10.1073/pnas.2002917117 pmid: 33020270
[22]	Cherng YG, Chu YC, Yadav VK, et al. Induced mitochondrial alteration and DNA damage via IFNGR-JAK2-STAT1-PARP1 pathway facilitates viral hepatitis associated hepatocellular carcinoma aggressiveness and stemness[J]. Cancers (Basel), 2021, 13(11): 2755. DOI: 10.3390/cancers13112755. doi: 10.3390/cancers13112755
[23]	周蔚文, 孙晓南. 肝外胆管癌放疗的研究进展[J]. 国际肿瘤学杂志, 2020, 47(7): 431-435. DOI: 10.3760/cma.j.cn371439-20200224-00051. doi: 10.3760/cma.j.cn371439-20200224-00051
[24]	Sheng H, Huang Y, Xiao Y, et al. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma[J]. J Immunother Cancer, 2020, 8(1): e000340. DOI: 10.1136/jitc-2019-000340. doi: 10.1136/jitc-2019-000340
[25]	Xie Y, Liu C, Zhang Y, et al. PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair[J]. PLoS One, 2021, 16(10): e0258817. DOI: 10.1371/journal.pone.0258817. doi: 10.1371/journal.pone.0258817
[26]	Gerossier L, Dubois A, Paturel A, et al. PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles' heel?[J]. Clin Res Hepatol Gastroenterol, 2021, 45(5): 101553. DOI: 10.1016/j.clinre.2020.09.014. doi: 10.1016/j.clinre.2020.09.014
[27]	Chen Y, Wang X, Deng X, et al. DNA damage repair status predicts opposite clinical prognosis immunotherapy and non-immunotherapy in hepatocellular carcinoma[J]. Front Immunol, 2021, 12: 676922. DOI: 10.3389/fimmu.2021.676922. doi: 10.3389/fimmu.2021.676922
[28]	李华兰. XPC、ERCC1及XPF表达与肝细胞癌临床病理特征及预后的相关性研究[D]. 南宁: 广西医科大学, 2019. DOI: 10.27038/d.cnki.ggxyu.2019.000139. doi: 10.27038/d.cnki.ggxyu.2019.000139
[29]	Liao X, Li Y, Li H, et al. Expression and clinical significance of ERCC1 and XPF in human hepatocellular carcinoma[J]. Onco Targets Ther, 2020, 13: 1059-1072. DOI: 10.2147/OTT.S237916. doi: 10.2147/OTT.S237916
[30]	Chen X, Legrand AJ, Cunniffe S, et al. Interplay between base excision repair protein XRCC1 and ALDH2 predicts overall survival in lung and liver cancer patients[J]. Cell Oncol (Dordr), 2018, 41(5): 527-539. DOI: 10.1007/s13402-018-0390-8. doi: 10.1007/s13402-018-0390-8